Effectiveness of a clinician-laboratory collaborative proactive follow-up management model in improving the HBV/HCV care cascade: A real-world controlled study
This real-world controlled study demonstrates that a hospital-based proactive follow-up management model integrating clinician and laboratory resources significantly improves care cascade completion, treatment uptake, and virological outcomes for patients with HBV and HCV infections compared to routine care.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For millions of people around the world, a diagnosis of chronic viral hepatitis is not just a medical label; it is the beginning of a long, often fragmented journey. The viruses that cause hepatitis B and C, known as HBV and HCV, can silently damage the liver over decades, leading to severe illness or cancer. While modern medicine has developed powerful drugs that can control or even cure these infections, a significant gap remains between finding the virus and getting the patient the treatment they need. This gap, often called the "care cascade," is where many people get lost. A patient might be tested in a hospital, receive a positive result, and then simply walk away, never seeing a specialist, never confirming the diagnosis, and never starting the medication that could save their life. The challenge for doctors and health systems is no longer just about having the right drugs available; it is about building a bridge that guides a patient from the moment of discovery all the way to a healthy outcome.
Researchers at the Affiliated Hospital of Youjiang Medical University for Nationalities in China decided to test a new way to build that bridge. They wanted to see if a hospital could do better than the standard way of handling positive test results. In the usual system, when a lab finds a virus, the result sits in a computer system, and the doctor who ordered the test might mention it to the patient. If the patient is lucky, they are told to go see a specialist. If they are not, or if they forget, the process stops there. The researchers proposed a different approach: a proactive, team-based system where the hospital actively chases the patient to ensure they get care. They set up a model where a dedicated case manager, working closely with the laboratory and infectious disease specialists, would take charge of every positive case. This manager would contact the patient, explain the results, help them make appointments, and follow up to make sure they stayed on track. To see if this worked, they compared two groups of patients: one group managed in the second half of 2023 under the old, routine system, and another group managed in the second half of 2024 under this new, proactive system.
The results of this real-world experiment were striking. The study looked at more than 1,500 people with hepatitis B and over 660 people with hepatitis C. Under the old routine system, less than half of the people with hepatitis B completed the full journey from screening to treatment and follow-up. For hepatitis C, the number was even lower, with only about one in four patients finishing the process. However, when the new proactive model was introduced, the numbers changed dramatically. With the new system, nearly 90% of people with hepatitis B completed the entire care cascade, and over 83% of those with hepatitis C did the same. The difference was not just a small improvement; it was a fundamental shift in how many people actually received the help they needed. The researchers found that the new system successfully linked patients to specialists, confirmed diagnoses, and got them started on antiviral therapy at rates far higher than before.
Beyond just getting patients into the system, the new model also improved the actual health outcomes. For those who started treatment, the virus was suppressed more effectively in the new group. In the hepatitis B group, nearly 79% of treated patients achieved a strong viral response, compared to only about 53% in the old group. For hepatitis C, which is often curable with a short course of medication, the success rate of clearing the virus completely rose from about 64% to nearly 96%. This suggests that when patients are actively guided through the process, they are more likely to stick with their treatment and achieve the best possible result. The study also looked at who was most likely to get lost in the old system. It found that older patients and those with less formal education were at higher risk of dropping out, highlighting that the new system's personalized support was particularly valuable for these vulnerable groups.
The researchers concluded that the key to solving the problem of viral hepatitis is not necessarily inventing new drugs, but rather reorganizing how hospitals deliver care. By integrating the laboratory, which finds the virus, with the clinical team, which treats it, and adding a dedicated person to manage the connection, the hospital created a safety net that caught patients who would otherwise have fallen through the cracks. This approach did not require expensive new technology or a massive increase in staff; it relied on better communication, clear responsibilities, and a commitment to following up with every patient. The study demonstrates that when a health system takes the initiative to reach out rather than waiting for patients to return, it can dramatically improve the lives of those living with chronic viral infections, turning a diagnosis into a path toward recovery.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.